

November 1, 2019



# Khiron To Participate in Cowen 2nd Annual Boston Cannabis Conference

*Company will present to institutional investors and join panel discussions covering developments in the cannabis industry*

TORONTO, Nov. 1, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce its participation in the Cowen 2<sup>nd</sup> Annual Boston Cannabis Conference, taking place Tuesday, November 12<sup>th</sup> to Wednesday, November 13<sup>th</sup>, 2019 in Boston, MA.



Hosted at the Intercontinental Hotel, the event will provide first-hand updates to institutional investors on marketed and emerging products across the spectrum of the cannabis industry. Fifteen high-interest panel discussions, covering topics including CBD In Retail, Sustainability, Payments, Regulatory and Legislation, US brands and international markets, will be held with thought-leaders and senior management from the industry's leading cannabis companies.

Alvaro Torres, Khiron CEO and Director, and Chris Naprawa, Khiron President, will present at the conference, and will be available for pre-scheduled one-on-one meetings. Mr. Torres will also join the conference's panel discussion covering international markets.

Conference details can be found here:

[https://www.meetmax.com/sched/event\\_58661/conference\\_home.html](https://www.meetmax.com/sched/event_58661/conference_home.html)

## **About Khiron Life Sciences Corp.**

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both

tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

## **Cautionary Notes**

### **Forward-Looking Statements**

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at [www.sedar.com](http://www.sedar.com). The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

### **United States Disclaimer**

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Further information in respect of the Company can be found at [www.khiron.ca](http://www.khiron.ca).

 View original content to download multimedia <http://www.prnewswire.com/news-releases/khiron-to-participate-in-cowen-2nd-annual-boston-cannabis-conference->

[300949597.html](http://300949597.html)

SOURCE Khiron Life Sciences Corp.